Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00WEQ
|
|||
| Former ID |
DNC011760
|
|||
| Drug Name |
Brolamfetamine
|
|||
| Synonyms |
Brolamfetamine; 2,5-Dimethoxy-4-bromoamphetamine; 4-Bromo-2,5-dimethoxyamphetamine; DOB-4; 4-Bromo-2,5-dimethoxyphenylisopropylamine; 4-Bromo-DMA; 32156-26-6; 2,5-Dimethoxy-(4-bromo)phenylisopropylamine; 64638-07-9; 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine; 1-(2,5-Dimethoxyphenyl-4-bromo)-2-aminopropane; 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane; 4-Bromo-2,5-dimethoxy-alpha-methylbenzeneethanamine; CHEMBL6607; DOB; DEA No. 7391; Benzeneethanamine, 4-bromo-2,5-dimethoxy-alpha-methyl-; Brolamfetaminum
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H16BrNO2
|
|||
| Canonical SMILES |
CC(CC1=CC(=C(C=C1OC)Br)OC)N
|
|||
| InChI |
1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
|
|||
| InChIKey |
FXMWUTGUCAKGQL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 64638-07-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3249526, 7516923, 8187862, 10518483, 10531667, 15071198, 43119241, 46507989, 47359939, 47805577, 50064682, 50113080, 50566377, 57314585, 85208881, 103164704, 103918766, 104324859, 117388967, 124893454, 127913862, 134223389, 134348965, 135028812, 135057191, 135650198, 135651149, 137005383, 160964741, 164840081, 179293614, 227004198, 241061107, 249912203, 252330132
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Inhibitor | [2] |
| 5-HT 1D receptor (HTR1D) | Target Info | Inhibitor | [2] | |
| 5-HT 2A receptor (HTR2A) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Calcium signaling pathway | ||||
| Gap junction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 163). | |||
| REF 2 | 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. | |||
| REF 3 | 'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg Med Chem. 2008 Jun 1;16(11):6242-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.